paritaprevir + ritonavir + dasabuvir + ribavirin

**Paritaprevir + ritonavir + dasabuvir + ribavirin** is an oral combination regimen used for the treatment of chronic hepatitis C virus (HCV) infection, particularly genotype 1[1][2][3][5][7][8][9]. Paritaprevir is an HCV NS3/4A protease inhibitor; ritonavir acts as a pharmacokinetic enhancer by inhibiting CYP3A to boost paritaprevir levels; dasabuvir is a non-nucleoside NS5B polymerase inhibitor; and ribavirin is a nucleoside analog with broad-spectrum antiviral activity. Used together, these agents block multiple steps in the HCV lifecycle, leading to robust viral suppression. With this four-drug combination, cure rates in genotype 1 HCV approach or exceed 95%, including in some difficult-to-treat populations such as patients with inherited bleeding disorders or compensated cirrhosis[3][5]. AbbVie developed and commercialized this multi-drug regimen, sometimes referred to as part of Viekira Pak when ombitasvir is included[5][9]. Treatment duration typically ranges from 12 to 24 weeks based on genotype, cirrhosis status, and prior treatment experience[5][8].